Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
" Administration is taking a look at it now. They’ll get it straightened out."
so if im still here in a few days, then that will mean you are full of shit...
sounds good to me...
I personally am getting a vibe that KBLBs share price will be in the dollar range very soon.. moving on to multiple dollars before we naturally uplist to the nasdaq. Is it really that hard to imagine that this company could soon be worth billions if not 10’s of billions of dollars within the next 12 months?
We have a unique, game changing product. Endless possible uses. Contracts, partnerships, royalties.
I cannot understand why some people stay on a stock board every single day just to bash it. If you are a paid basher, well then I guess it’s your job.
Me personally, I don’t read any stock boards that I’m not affiliated with never less post on these boards daily.
If you don't have the funds to buy shares and missed the boat, then I am truly sorry. But don’t hang around in envy of us long term shareholders. Life is too short. Go for a walk and get an ice cream.
But it’s a free world. Do what you like. Just don’t expect me to think you actually have a life.
Just saw your comment, was curious, checked a couple of things you said were bs and addressed that for grins and certainly not upset. Hope they get this major issue resolved, lol...
The road is paved. We don’t need a Goldwin at 10% lol. We don’t need $200M private financing. We just need to focus on producing silk where our feet are at. Lam Dong. VSA. Silk. Silk. Silk. Just make a lot of it and put it in the hands of M et al and we’re off to the races! The hard part seems to be over with. Just maintain the heading and produce cocoon after cocoon. Again, the road is paved. The future is so bright we gotta wear shades.
Yes, that's gonna keep some up all night, TBM?
You’re awfully concerned ? No worries. Administration is taking a look at it now. They’ll get it straightened out. Thumbs up. Not sure why you’re so upset about it.
Which mojo is the bigger tool, THAT is the question.
Facts say 6-22 and 7-6, so yeah, seriously. Perhaps and so what?
June 22 and July 7th are the same day?
I don’t see a connection between the two screen names other than that they both have “mojo” in the name.
They don’t even post on the same board. So what’s the point?
I don’t see any duplicity even if they were the same person. I’m not seeing the scandal here.
I have no interest in DJT boards at all, and the odds are no good since they are not the same.
Don't care about all the other whatever your beef is...just addressing your same date, same time crap. Go after them all you want.
igotthemojo
Level Icon
Followers 78
Posts 20,964
Boards Moderated 0
Alias Born 07/07/2006
Mojocash
Level Icon L2 Icon
Followers 446
Posts 30,108
Boards Moderated 1
Alias Born 06/22/2006
Mojo is a fake. Years ago he was so against KBLB it pissed me off. Non stop he was going after them. Now he’s praising them. Don’t get me wrong. I want you all to succeed, but he has 2 different accounts. And if he pisses me off enough, I’ll get him erased because he’s denying it.
Let’s say even if it was 2 weeks apart ?!?! Seriously ?!?! It’s the same person. 2 different aliases !!
ARE YOU ON DRUGS ?!
How interesting, go to DJT and look at mojo’s post. Look at the join date !! Look at the join date on Kblb of mojo. The exact same date under different MOJO names. What are the odds my friend !!!!
So you say, "So they were NOT created the same day ?!?! Seriously ?!"
Duh, seriously! 6-22-2006 and 7-7-2006 need I say more, quit making shit up and lying. What are you trying to prove? How wonderful your due diligence is? I don't have a dog in this hunt, so have at it!
So they were NOT created the same day ?!?! Seriously ?!
No they were not...quit lying...
KBLB is undervalued until it gets to .18 cents pps. Then it is anybody’s guess after that. That’s what I believe. But .18 cents seems fair for where they are (and were about to be several years ago). And I am factoring in the increased shares outstanding otherwise I’d say .26 cents.
No they were not...quit lying...
Phrases I'm sick of seeing on here:
"Soon"
"Any day"
"Next week"
"About to explode"
"Days, weeks ahead"
"Coming months"
All of you idiots keep alternating posts with these phrases and none are accurate. And whomever said .25 by Friday was a moron.
CAN SOMEONE PLEASE post actual, thought out time frames?
I'll start with what I'm looking forward to.
Based on a recent PR, METRIC Tonnage could be announced in or by late June. It seems everyone agrees this will hit $1.
July and August could see products.
September more metric tonage.
October contracts.
December MORE production.
At this point we should be back on the NASDAQ.
The DOD grants will be announced before 2025. KT has an action he can take on 2 million shares in or by February of 2025.
Kim cashes out shortly after.
Then what?
What other milestones am I missing?
No they were not...quit lying...
It’s so great I called you out man !!! You are a fake !!
It’s LITERALLY the same Minute !!!!!! If you’re are calling me out you’re crazy !!!
Created on the same day ?!?!?! What are the odds ?!?! Ha !! You crazy mojo X 2 ! :))))
Wrong you clown. Look at the posting history. Lmao! Not even a stock in common. You cra cra!
Mojocash is his 2nd name. He’s not happy.
DJT has 2 boards, you have to go to the administrative board up top and pick the first one. Then you can see all of his rediculous posts. This has nothing to do with KNLB. But mojo is definitely a fake.
Did everyone know mojo has 2 aliases ? Look under DJT stock. You’ll be amazed. He’s a trumpster !! Both created in 2006 two weeks apart.
I’ll continue to sit in the bleachers but I’m hoping you all hit it big. $$$.
Can gaurantee that MM's for this stock are present on this board
“I am proud of the work accomplished and very impressed by the performance of the BAM-1 silkworm lines,” Dr. Nirmal Kumar, stated. “The luster of the BAM-1 silk is very unique and desirable. When paired with its strength, we have created a silk that can’t be matched. The results of these trials exceeded our expectations. We are now on a solid foundation to scale production of the BAM-1 hybrid to metric ton levels.”
Wow that pretty well says it all. I'm glad you're out so you don't have to worry about taxes. Tell your dad it's near. And your bashing isn't hurting at all.
Hey jetoe!!!
I LOVE HISTORY TOOO!!!!
As a big fan of history, I base my opinion on the facts at hand. Not pretty pictures. Not company released PRs. Not here say.
That’s why I like to reference that latest filing, which states
Increased share counts
As well as
Zero production
Zero revenues
Zero profits
This has been, with a small blip, a historically accurate statement since the companies inception. Gotta live that historical evidence.
Seems like there are profit takers at every level the SP gets too. The MM also bring the price down so "THEY" buy the shares cheaper and then sell them back into the market on a price upswing. They have more control than the law should allow. The MM shenanigans are well documented.
Ruskie.....The light of Jesus has finally shone on you. Waking up about KBLB is huge but still not late, and shares remain CHEAP. As I said yesterday, KBLB should be trading at .25 a share right now. Even from .118, that is still a double with more to come. GO KBLB!
BOOM!!! Harry and Lloyd should have pursued that worm farm dream. Now it's Kimbo and crew lol
“ If Kim does drop the big one will we have a muted reaction because of limited coverage?”
Don’t think so…delayed reaction from investors perhaps, but they will come…
Traders will jump on board and the pps will rise…investors will follow…
Latest PR on Schwab is still April 29. This needs to be fixed, NOW! If Kim does drop the big one will we have a muted reaction because of limited coverage?
“that fuse is lit bleacher watchers”
I agree ruskie 1 And looking forward to the grand network national television debut!
It won’t be long before lots of eyes and lots of money start chasing our shares.
Word to the wise ..All of you out there looking at this better get em now..gonna pay big time per share going forward from now on …that fuse is lit bleacher watchers
Kim’s back with liftoff on the mind. Might be the Last week to accumulate down here?
With Production success confirmed the news cycles should change to applications and partnerships…..
Nice chart uptick with volume to 0,117, and immediately brought down to 0,11, ask placed at 0,111....... Oh yes, the mms are behind this stock trying to keep it down..........But we will rise hard soon......
Funny how ALL the lies the 2 bashers used to push have been proven wrong. And all they have left is bringing up development stages from years ago lol.
Half a brain can see how successful Kblb is SMH
That PR is only 11 years old. Can you dig back and get earlier PRs that give revelance to where we are today?
It's really refreshing to see historians like you and Webslinger praise each other in your many searches.
As we move forward with a better understanding of the past, we realize what an accomplishment Kraig Biocraft has achieved. And with the recent announcement stating everything is a go for large mass production after trials by experts we look forward to the many rewards in our near future. Hopefully you and friends will be going on that journey with us after all the tireless hours in research in past PRs and accomplishments.
Thank you once again.
No personal comment, one just has to reread monday's pr, it explains where this company is headed, every opinion or comment not necessary, we have the golden Willy Wonka entrance ticket for the chocolate factory here, no more doubt at all.
Just the mms holding the pps down, no doubt that this is the case, they don't let it appear inn a positive chart trend, because it would immediately run fast with all the sideliners waiting and still hoping for cheap shares..........The news hasn't yet hit, but it will..........
KRAIG BIOCRAFT LABORATORIES SPRING PRODUCTION TRIALS EXCEED EXPECTATIONS FOR THE PRODUCTION OF THE COMPANY’S RECOMBINANT SPIDER SILK
ANN ARBOR, Mich., – May 6, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that the spring production trials of the Company’s new BAM-1 hybrid parental strains have concluded, exceeding all expectations for scale, performance and robustness.
Kraig Labs reports that the spring production trials were an unabashed success. These trials proved that the Company’s BAM-1 recombinant spider silk hybrids are ready for rapid production expansion. Simply stated, this has been the most fruitful and successful production cycle in the Company’s history.
Renowned sericulture expert and Kraig Labs executive consultant, Dr. Nirmal Kumar, oversaw the production cycle from start to finish, including rearing and selective breeding. Careful and meticulous testing throughout the entire production trial demonstrated that the BAM-1 parental lines were the strongest and most resilient lines Kraig Labs has ever developed.
Observation and screening conducted throughout all phases of production exceeded all expectations for health and vigor within the colony. Not a single instance of disease or infection was detected at any point during the entire cycle. This result surprised local silkworm experts observing the trials. Working with mundane silkworms, they had never experienced an entire production cycle from egg to egg without any disease in a batch of thousands of silkworms.
Under the guidance of Dr. Nirmal Kumar and through a meticulous, statistically-based selective breeding protocol, the parental strains for the BAM-1 hybrid were further optimized during the production cycle. The enhancements to the parental lines from this careful breeding program were designed to deliver larger cocoons with improved reeling characteristics and higher yields.
“I am proud of the work accomplished and very impressed by the performance of the BAM-1 silkworm lines,” Dr. Nirmal Kumar, stated. “The luster of the BAM-1 silk is very unique and desirable. When paired with its strength, we have created a silk that can’t be matched. The results of these trials exceeded our expectations. We are now on a solid foundation to scale production of the BAM-1 hybrid to metric ton levels.”
“The BAM-1 parental lines have proven to be the strongest and most resilient we have ever fielded,” said Company founder and CEO, Kim Thompson. “This production run greatly exceeded our targets and has prepared us for the next phase of our business plan. With these production trials successfully concluded, we are now aggressively implementing the next phase of our business plan, which will expand our operations and target multiple production locations in multiple countries.”
Thompson and Dr. Nirmal Kumar have spent the last two months directly overseeing these trials, selecting facilities for expansion, reviewing operational protocols, and meeting with officials and business leaders regarding the Company’s immediate plans. Thompson is now returning to the U.S. to enact the next stages of its spider silk production expansion plan and complete the Company’s transition from a technology developer to a large-scale spider silk manufacturer.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
More history lessons. As science and technology advances, so does the company. We now have true EXPERTS involved, on site, overseeing operations.
Strongly recommend everyone do their own due diligence. Anyone looking to draw your attention to information from a decade ago is unwilling to let go of the past. To move forward.
What KBLB is attempting to do has never been done before. The science keeps improving, making the past something to learn from but not something to dwell on IMO.
Look at post histories. Context is important. Anyone claiming to only seek the truth but who only posts about other companies and KBLB setbacks clearly has an agenda. Dig deeper.
Everyone has an agenda. Some are here hoping the company fails. Some are likely paid to push a negative narrative. Some want the company to succeed. I’m in that bucket. I don’t invest to complain. I don’t troll message boards for sport. But this is the OTC. Not for everyone. Being willing to take on risk for the potential for exponential gains is a decision everyone has to make based on their own financial situation and risk tolerance.
Know what you own. Going to be a very interesting next few months.
Tick tock…
W2R
<< 2013 - running ahead of schedule >>
Running "ahead of schedule" since 2013....
LOL
LANSING, Mich., Feb. 25, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company” or “Kraig”), the leading developer of advanced spider silk based fiber technologies, announced today that the first two stages of its Monster Silk™ pilot production program (“program”) are running ahead of schedule and that both stages of the program are on track to meet or EXCEED the program’s goals.
The production capacity for the first two stages EXCEEDS the Company’s prior maximum capacities by a factor of four or five.
The program is designed to be the basis of the Company’s large scale commercial production of its recombinant spider silks. The program is designed to run in three stages; with each successive stage launching when the previous stage’s data indicates that the program is reaching, or EXCEEDING, its benchmarks.
The current data supports the continued fast-tracking of the program, as the second phase is developing on track, SURPASSING the trial’s initial phase in terms of capacity and success rates. The first stage continues to run AHEAD OF EXPECTATIONS and is already moving to an advanced state.
“So far the pilot production program has EXCEEDED OUR EXPECTATIONS AND IS CONFIRMING THAT OUR PRODUCTION MODEL IS FULLY SCALABLE, as Phase II surpassed the program’s first phase, despite the fact that it’s a much larger trial,” said Kraig founder and CEO, Kim Thompson. “From the beginning, this has been an ambitious program, which now appears to be rewarding our efforts. We are continuing to rapidly advance through stage two of the production program.”
KRAIG BIOCRAFT LABORATORIES PROVIDES UPDATE ON THE MONSTER SILK(TM) PILOT PRODUCTION PROGRAM’S SECOND STAGE; PROGRAM IS ACCOMPLISHING ITS TARGETED MILESTONES AND REMAINS WELL AHEAD OF SCHEDULE
Care to explain?
"How Some Companies Are Making Textiles More Sustainable
TIME LINK"
Followers
|
641
|
Posters
|
|
Posts (Today)
|
29
|
Posts (Total)
|
281098
|
Created
|
05/04/08
|
Type
|
Free
|
Moderators MU_Redskin1 gimmegimmeminemine TRUISM WebSlinger |
Email: corporate@KraigLabs.com
KRAIG LABS WEBSITE FOR INVESTORS
Quarterly and Annual Reporting to the SEC is available on the Company's Website and EDGAR.
* Financial Statements * SEC Filings *
Outstanding Shares as of January 12, 2023
For issues or questions relating to share certificates or the transfer of securities please contact the company's transfer agent:
Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Pkwy.
Atlantic Highlands, New Jersey 07716
Phone: (732) 872-2727
(since August 14, 2013)
Kraig Biocraft Laboratories, Inc. (KBLB) is the first company with a commercially feasible spidersilk to be mass produced.
Kraig Labs is a biotechnology company focused on the development of commercially significant high performance polymers and technical fibers. Kraig Lab's focus has been on the production of a transgenic silkworm incorporating specific gene sequences from the golden orb weaving spider. These specific gene sequences inserted are to enable the silkworm to spin a new recombinant fiber which incorporates spider silk proteins. With the scientific breakthrough announced on September 29, 2010, Kraig Labs is now working to commercialize the transgenic silkworms to compete in the garment industry silk market. The value for the chinese raw silk market alone is 3-5 billion per annum. With the creation of 20 seperate transgenic silkworms, all with unique properties, Kraig Labs is now working at an accelerated pace to build upon their first generation transgenic organisms to develop their second generation of transgenic silkworm incorporating spider silk proteins. The scientists nearly doubled the strength of the silkworm with these specific spider gene insertions. Their second generation of transgenics are expected to be complete in 2011. These second generation organisms are to be compared with the strength, flexibility and resiliency of the native spider in which the gene sequences are derived from. These fibers which will match the strength of spider silk are expected to compete in the technical textiles market valued in excess of 120 billion per annum. The 3rd generation organisms are currently in the planning phase. These organisms are expected to spin fibers exceeding the strength of native spiders and may incorporate gene sequences that release an antibiotic, or to help reduce scarring with use in bandages.
Kraig Biocraft Laboratories has a sponsored research and development program with the University of Notre Dame, and the University of Wyoming. The genetic work is occurring at the University of Notre Dame, headed by Dr Malcolm Fraser, Phd. The gene sequences are derived from Dr. Randy Lewis's(University of Wyoming) patented gene sequences of the golden orb weaving spider. Kraig labs is paying for all expenses incurred for this research and development program, and thus Kraig Labs has exclusive global commercialization rights with the technologies developed, including methods, organisms, and fibers produced.
MANAGEMENT
Kim Thompson, Founder and CEO
As the CEO of the company, Mr. Thompson is the only member of the scientific advisory board who is also
a part of the corporation's management. His formal education lies in the fields of economics and law.
He received his B.A. in Applied Economics from James Madison College at Michigan State University.
He received his Juris Doctorate from the University of Michigan Law School in 1994.
Mr. Thompson founded Kraig Biocraft Laboratories in his pursuit of the development of new biotechnologies
with industrial applications. As chairman of the scientific advisory board, he brings a unique perspective,and
acts as the primary liaison between the advisory board and the corporation.
Mr. Thompson brings a wealth of experience in business management and consultation to Kraig. Following
the completion of his undergraduate degree, Mr. Thompson joined California Craftsman, Inc. as a
Vice-President with primary responsibility for both marketing and human resources.
Kim Thompson was the director of business development at Franchise Venture Partners, LLC. He subsequently
joined the firm of Shearson, Lehman, Hutton where he specialized in equity trading and research of small cap
companies. Mr. Thompson received the highest series seven score for all Shearson brokers in his class nationwide.
His experience in those small cap equity markets has proven to be invaluable both in his legal and business successes.
Prior to becoming a public company CEO, Mr. Thompson was the founder and senior litigation partner in a California
commercial law firm where he worked as corporate and litigation counsel to privately held and public companies.
His many accomplishments in corporate law include winning and collecting in full what his firm believes to have been
the largest award of lost profits in a California commercial arbitration up to that time. An important part of his work was
winning victories on behalf of corporate clients in disputes over intellectual property and distribution rights. He has
represented business clients ranging from small start ups and micro caps to Fortune 100 companies.
With a background in business leadership and in advising public and private corporations, Kim Thompson continues
to bring a unique perspective to the successful management of business. His extensive business and legal background
enables him to create practical solutions to business problems and seize opportunities for growth.
Mr. Thompson is a member of the Triple Nine Society for persons with documented genius level IQs (having tested above
the 99.9th percentile). He is also active in the realm of science and invention where he has to his credit a number of
provisional patent applications including innovations in the areas of biotechnology, organic polymers, genetic engineering
and magnetic field manipulation, among others.
Mr. Rice has over 13 years’ experience growing development stage businesses with a focus on technology development, commercialization, and go to market strategies. Mr. Rice holds a B.S. in Chemical engineering from Michigan Technological University.
Prior to joining Kraig Biocraft Laboratories Mr. Rice was the Director of Advanced Technologies for Ultra Electronics, AMI. In this role, Mr. Rice was responsible for the identification, capture, and execution of new technology programs. During his tenure with AMI, Rice secured more than twenty five million dollars in funded development programs from the US Department of Defense which his team successfully leveraged into commercially viable spinoff products. Mr. Rice was also responsible for technical sales, marketing, and promotion of AMI’s products and capabilities. Rice joined AMI as the third full time employee and helped to lead the organization through its rapid growth and ultimate acquisition by Ultra Electronics in 2011.
Earlier in his career Mr. Rice developed unique advanced manufacturing techniques, established and trained a production staff, led engineering development, authored numerous technical papers, and is a recognized subject matter expert. Mr. Rice holds 5 issued patents and numerous provisional patents.
Mr. Rice brings a history of transforming revolutionary ideas into viable commercial products.
Mr. Rice is currently completing his Masters of Business Administration through the Executive Program at the Eli Broad College of Business: Michigan State University.
Despite the huge potential of genetically modified animals outside of laboratory research, commercialisation of these animals has been extremely limited. Numerous factors, including negative consumer perception, regulatory hurdles, and limitations inherent to classical GM technologies, have kept the majority of GM animal applications within the realm of academic research. However genome editing using zinc finger nucleases could help develop new markets for the future commercialisation of GM animals.
Genetic modification is commonplace throughout the life sciences sector, from fundamental research to pharmaceutical testing. GM cellular and animal models are valuable tools for the study of many chronic diseases, the testing of pharmaceutical compounds and the development of new therapeutic strategies. Genetic modification also offers great benefits in vaccine and biopharmaceutical manufacturing, which rely heavily on the use of GM organisms for biomolecule design and production. Modifying the genome of an organism or cell line allows the incorporation of target biomolecules in specific biological contexts, as well as the transfer of a gene product from a low-producing organism to one that can produce on a commercial scale. These applications have been widely accepted for many years, with countless GM organisms approved for medical manufacturing applications by drug regulators in all major countries. Despite this widespread success within the research and pharmaceutical sectors, the use of GM organisms outside of these markets has been limited.
Despite the lack of broad acceptance for most commercial applications of GM animal products, this technology has been able to gain traction in a few market sectors. The most obvious application has been the commercialisation of transgenic animals for the production of biomolecules for therapeutic use. Cattle, sheep and goats have been used for large-scale production of antibodies, steroids and hormones - most notably insulin - for many years. In 2009, GTC Biotherapeutics received US FDA approval for bioproduction of a recombinant human antithrombin. This product - ATryn - is extracted from the milk of transgenic goats, and is the first approved biopharmaceutical to be produced using genetically engineered animals. Although this is a significant breakthrough for the commercialisation of GM animals, it is still within the pharmaceutical industry, and is a natural progression of existing cell-based technologies. Of potentially greater commercial interest is the extension of genetic engineering outside of this sector, into areas such as food production, textiles and even companion animals.
GM crops have been available in many countries since the early 1990s, and numerous cash crops - including sugar beet, soybean, corn and tomatoes - have been modified to improve resistance to disease, increase the rate of growth or enhance nutritional value. However, cultivation of these transgenic crops is generally tightly regulated, particularly within the European Union, and this, together with negative public opinion, has limited the more widespread development of GM technologies.
Similar to GM crops, many of the animals currently under development are intended to confer disease resistance, an application particularly suited to the use of zinc finger nuclease (ZFN) technology. Many diseases can be treated by the targeted deletion or modification of a host gene. With ZFNs, these targets can be modified with no footprint of genetic engineering. Due to the high costs of raising livestock, another area of focus in developing commercial GM animals has been increasing the rate of growth or size of animals. Among the first GM animals likely to be launched is a fast growing salmon from AquaBounty. The AquAdvantage Salmon is designed to reach market size in half the time of a wild type salmon, reducing costs for fish farmers and limiting the environmental impact of salmon farming by avoiding the need for ocean pens.
Although genetic engineering of animals for food is primarily driven by economic pressures, GM technologies have also been used in the companion animals market. In this sector, genetic modification can be used for practical purposes - such as the creation of hypoallergenic animals or the correction of heritable congenital defects which have arisen though inbreeding - or for purely cosmetic purposes, such as GloFish. The first example of a GM pet, GloFish are fluorescent zebrafish (Danio rerio) that have had genes encoding naturally fluorescent proteins (GFP, YFP, RFP) inserted into their genome. Developed by a group at the National University of Singapore, GloFish were originally created to develop live detection systems for water pollution. They were introduced as pets in the United States in 2003 following over two years of extensive environmental research and consultation. In Europe however, the sale and possession of GloFish is prohibited by rigorous legislation concerning the use of GM technologies.
By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels
Perhaps even more interesting from a commercial perspective is the use of GM animals in the manufacture of textiles. Silkworms - actually the larval form of the silkmoth Bombyx mori - have been used for the production of silk for thousands of years, with natural silk still produced by the cultivation of silkworms today. Silkworm cocoons are unwound to create linear silk threads, then re-spun into textiles in much the same way as cotton. Although the applications of silkworm silk are numerous, due to their unique physical and chemical properties, there is also widespread interest in the silks of several other insects.
Spider silk, in particular, offers numerous possibilities within the technical textiles industry, due to its incredible tensile strength and elasticity; characteristics which have not yet been replicated in synthetic materials. Like all insect silks, spider silk fibres consist of repetitive units of protein crystals separated by less structured protein chains. The exact properties and composition of each spider silk vary with its intended function. Major Ampullate or dragline silk, for example, is relatively hydrophobic with very high tensile strength and toughness, as it is used to form the outer rim and spokes of a web. In contrast, hydrophilic capture spiral silks, which form the inner structures of the web, are sticky and highly elastic to effectively entrap prey. This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics, for applications such as bulletproof vests, parachute canopies and automobile airbags; biomedical applications, including sutures and tendon and ligament repair; new fabrics, for sportswear and clothing; and even microelectronics.
Although the use of spider silks for microsutures has recently been reported, more widespread application of spider silk technologies is currently limited by the difficulty in producing silks on a commercially viable scale. This is due to the difficulties of rearing spiders in large numbers, due to their highly territorial and cannibalistic nature. As a result, the harvesting of spider silk fibres is extremely time consuming and labour intensive, with production of the only known spider silk garment - an 11 foot by 4 foot shawl made from golden orb spider silk - taking 150 people over five years to produce and costing in excess of £300,000!
.
To overcome these limitations, and allow future development of spider silk technologies, an alternative strategy for spider silk production is required. This makes spider silk production an obvious candidate for genetic modification, inserting spider silk genes into the genome
of other silk-making insects for bioproduction. For example, random insertion of orb spider silk genes into silkworms has allowed production of hybrid spider/silkworm silk using traditional silkworm farming strategies. The resulting hybrid silk contains approximately 10% spider silk
and has greater strength and durability than native silkworm silk, raising the possibility of using transgenic silkworms to produce pure spider silks.
Though straightforward in principle, the exchange of native silkworm genes for spider silk genes, alongside more widespread exploitation of genetic engineering, has been limited by the inherent restrictions of conventional GM technologies.
The generalised process of modifying an organism requires several capabilities, including:
While many different techniques exist for accomplishing each of these steps, most GM technologies offer a compromise between the efficiency of the technique and the ability to accurately and precisely target the locus of interest. Viral genomic delivery technologies effectively deliver nucleic acids to cells and organisms, but fall short on ability to target specific regions of the genome, generally only allowing random insertion of genetic material. In comparison, transposase technologies allow a greater degree of targeting, but leave unwanted traces of exogenous DNA in their wake. Other methods involve the introduction of naked DNA into the cell, which results in insertion into the genome at very low frequencies, usually at random, limiting this approach to organisms that can be economically cultivated at high densities and screened in large numbers. Simply put, most techniques for genetic manipulation are random, inefficient and leave a 'footprint' of foreign DNA. While this is usually tolerated in basic research, it is not acceptable for most commercial applications, and has been a major hurdle for GM animal technologies to date.
The advent of zinc finger nuclease (ZFN) technology represents a significant breakthrough for commercialisation of GM animal products, offering precisely targeted, efficient genome editing for the first time. Commercially available through Sigma Life Science under the CompoZr brand, this technique can be used to create permanent and heritable changes to an organism of interest.
This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics
ZFNs are a class of engineered DNA binding proteins that facilitate targeted editing of the genome by creating double-strand breaks at user-specified locations. These breaks stimulate the cell's natural DNA repair mechanisms - homologous recombination (HR) and non-homologous end joining (NHEJ) - which can be exploited to achieve rapid and permanent site-specific modification of the desired genes. While HR can be used to insert foreign DNA sequences, NHEJ allows the cell's natural processes to create precisely targeted mimics of natural mutations which leave no traces of foreign DNA. Unlike previous techniques, ZFNs offer excellent sequence specificity, binding 24 to 36 base pair target sequences to virtually eliminate off target effects, and are able to achieve modification rates exceeding 20 %, well above rates for most other technologies.
The technique is already being used to create transgenic silkworms for spider silk production. By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels.
GM technologies have revolutionised the research world and have great potential in a variety of commercial applications, but have been limited by the inherent restrictions associated with historical GM technologies. The main drawback of these technologies is their inability to accurately and efficiently target genes of interest, instead relying on random insertion of genetic material into host genomes. These limitations result in the need for extensive and costly screening to identify animals with correct transgene expression (without compromising the viability of the animal), and also result in the co-expression of both the transgene and native homologues already present.
The advent of ZFN technology signifies the beginning of an exciting new chapter in the world of genetic modification, allowing precise, targeted and efficient genome editing for the first time. Production of native spider silk using transgenic silkworms is just one example of the potential commercial applications of this innovative technology, taking us one step closer to the reality of industrial scale biomanufacturing and paving the way for an entirely new spectrum of environmentally friendly materials.
Authors:
Joseph Bedell and Brian Buntaine
Commercial Animal Technologies Group, Sigma Advanced Genetic Engineering (SAGE) Labs, Sigma Life Science
HEADLINES FOR KRAIG BIOCRAFT LABORATORIES / (KBLB):
PHOTOS FROM VIETNAM POSTED JULY 6, 2018
ANN ARBOR, Mich., – January 7, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has successfully delivered the first two shipments of its highly specialized silkworms, which produce a silk with the physical characteristics of spider silk, to Vietnam.
Today’s announcement is the culmination of more than 5 years of work, and challenging negotiation, with the government of Vietnam. The silkworms from these first two shipments have already hatched and are now enjoying a fresh mulberry diet, so, for the first time in history, the global demand for spider silk materials has a viable, cost effective, and scalable solution.
“The dream of commercializing our powerful technology is now materializing. This marks a dramatic leap forward in Kraig Labs’ business plan for commercial production and mass marketing of cost effective recombinant spider silk, and becomes the foundation for an entirely new industry,” said, COO, Jon Rice. “To our long-term shareholders, who have taken this journey with us, as well as our team in the US and Vietnam, who have worked tirelessly to make this dream a reality, I cannot thank you enough. As we start the New Year, full of new opportunity, we truly have something incredible to celebrate.”
The Company has been working with leading sericulture experts, biotechnology institutions, and governmental agencies, in Vietnam, to further boost the silk industry with our revolutionary technology. Kraig Labs is currently finalizing renovation plans for a ~46,000 square foot production factory in Quang Nam Province, Vietnam.
“Our plan has always been to bring our technology to the silk producing regions of the world for rapid scale-up,” said, CEO and Founder, Kim Thompson. “Today we see the fruits of that effort. With its massive silk infrastructure and production capacity, Vietnam is an ideal location to launch our technology scale-up. Congratulations to our team and shareholders, as we prepare for the realization of large scale production.”
\
\
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |